Physician profile
Kassi A Sexton
NPI 1689019341
$913.33
in general payments reported to CMS, 2019-2025
10 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $239 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.33 | 2024-2025 | |
| Pfizer INC. | $168.39 | 2024-2025 | |
| Novo Nordisk INC | $159.78 | 2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $100.25 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $84.75 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $65.14 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $29.50 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $25.08 | 2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $24.92 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $15.19 | 2024 | Vaxneuvance, Capvaxive, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kassi Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.